- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06846099
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
A Phase I/Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of Pl3Kα-Selective Inhibitor RP903 (JS105) in Subjects With Advanced Malignancies
Study Overview
Status
Intervention / Treatment
Detailed Description
Phase Ia is divided into two phases of dose escalation and dose extension: This part includes dose escalation and dose extension of RP903 single agent to investigate the safety, tolerability, maximum tolerated dose and pharmacokinetic (PK) characteristics of RP903 single agent.
Phase Ib is the clinical indication expansion phase, and the primary purpose of this phase is to evaluate the initial safety and anti-tumor efficacy in a selected indication target population. After determining RP903 monotherapy RP2D in Phase Ia, SMC will select four advanced malignant tumors with PIK3CA mutations (cervical cancer, endometrial cancer, breast cancer, and ovarian cancer) as indications for clinical expansion studies based on phase Ia efficacy, safety, and pharmacokinetic (PK) data. The dose was determined according to the results of the dose escalation phase and the dose extension phase.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Beijing Cancer Hospital
-
Bengbu, China
- the First Affiliated Hospital of Bengbu Medical College
-
Changchun, China
- Jilin cancer hospital
-
Changchun, China
- Jilin University First Hospital
-
Chengdu, China
- Sichuan Cancer Hospital
-
Chongqing, China
- Chongqing University Cancer Hospital
-
Fuzhou, China
- Fujian Medical University Union Hospital
-
Fuzhou, China
- Fujian Cancer Hospital
-
Hangzhou, China
- Zhejiang Cancer Hospital
-
Hangzhou, China
- Sir Run Run Shaw Hospital
-
Harbin, China
- Harbin Medical University Cancer Hospital
-
Jinan, China
- Shandong Cancer hospital & institute
-
Jining, China
- Affiliated Hospital of Jining Medical College
-
Linyi, China
- Linyi Cancer Hospital
-
Luoyang, China
- The First Affiliated Hospital of Henan University of Science and Technology
-
Nanning, China
- Guangxi Medical University Cancer Hospital
-
Qingdao, China
- The Affiliated Hospital of Qingdao University
-
Shanghai, China
- Affiliated Cancer Hospital of Fudan University
-
Shenyang, China
- LiaoNing Cancer Hospital&Institute
-
Suining, China
- Suining Central Hospital
-
Wuhan, China
- Hubei Cancer Hospital
-
Yinchuan, China
- Ceneral Hosipital of Ningxia Medical University
-
Zhengzhou, China
- Henan Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Agreement to provide fresh or archived tumor tissue sample within 3 years
- Ia (dose escalation phase and dose expansion phase):patients with pathologically confirmed advanced Malignant solid tumour who have experienced Treatment failure, are unable to tolerate standard treatment, or have no standard treatment
- Ib: Patients with advanced malignant solid tumours who have PIK3CA activating mutations, experience treatment failure, are intolerant to standard treatment, or have no standard treatment
- Phase Ia: Solid tumour, not limited to specific types; dose expansion phase will prioritize cervix carcinoma, endometrial cancer, ovarian cancer, and breast cancer.
- Phase Ib:Cervix carcinoma (Expanded Cohort 1):Having received first-line (including Platinum-based chemotherapy ± bevacizumab) or second-line treatment and having disease progression during or after treatment; (recurrence during or within 12 months after neoadjuvant or adjuvant treatment in previous treatment will be regarded as one treatment line)
- Phase Ib:Endometrial cancer (extension cohort 2):Progression during or after first-line (including platinum) or second-line treatment of advanced or metastatic disease; (recurrence during or within 12 months after neoadjuvant or adjuvant treatment in previous treatment will be considered as one treatment line);Sarcoma type not included
- Ovarian cancer (expanded cohort 3) (PIK3CA mutation):
- Ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma who have experienced treatment failure or are intolerant to at least one line of cytotoxic therapy ± PARP inhibitor; (recurrence during or within 12 months after neoadjuvant or adjuvant therapy will be considered one line of therapy)
- Pathological types include high-grade serous carcinoma, clear cell carcinoma, or Endometrioid carcinoma
- Breast cancer (extension cohort 4) (PIK3CA mutation):
- Advanced, recurrent and metastatic breast cancer;
- Prior systemic treatment in at least 1 line and no more than 3 lines (patients who have relapsed during or within 12 months after completion of neoadjuvant/adjuvant endocrine therapy will be considered as one line of endocrine therapy)
- At least one measurable lesion as per RECIST v1.1 (except the dose-escalation phase of monotherapy)
- Eastern Cooperative Oncology Group (ECOG) performance status score: 0-1
- Adequate hematologic and organ function
Exclusion Criteria:
- Patients with known allergy to any component of RP903
- Previously treated with PI3K, mTOR or AKT inhibitors
- Systemic anti-tumor therapy within 4 weeks prior to the first dose
- Presence of leptomeningeal or meningeal metastasis, or presence of signs of carcinomatous Meningitis
- Metastases to bone marrow
- Child-Pugh grade B or C
- Active hepatitis B or C
- History of type I Diabetes mellitus,gestational diabetes or uncontrolled type II Diabetes mellitus
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: RP903 arm
Ia:Participants will receive RP903 in escalating dose levels with starting dose of 50mg, po qd for each 28-day cycle Ib:Participants will receive RP903 with RP2D, po qd for each 28-day cycle
|
Ia:RP903 50mg, 100mg, 200mg, 300mg,350mg,or other dose, po qd for each 28-day cycle; Ib: RP903,RP2D,po qd for each 28-day cycle
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ia:dose-limiting toxicity(DLTs)
Time Frame: 28 days
|
Incidence and severity of dose-limiting toxicity (DLTs)
|
28 days
|
|
Ia:Adverse Events
Time Frame: 2 years
|
Incidence and severity of Adverse Events(AEs) according to NCI-CTCAE
|
2 years
|
|
Ia: serious adverse events
Time Frame: 2 years
|
Incidence and severity of serious adverse events(SAEs) according to NCI-CTCAE
|
2 years
|
|
Ia: Abnormal changes in Laboratory test and other abnormalities
Time Frame: 2 years
|
Incidence and severity of abnormal changes in Laboratory test and other tests with clinically significant according to NCI-CTCAE
|
2 years
|
|
Ia: MTD
Time Frame: 2 years
|
Maximum Tolerated Dose(MTD)
|
2 years
|
|
Ia: MAD
Time Frame: 2 years
|
Maximum Administrated Dose(MAD)
|
2 years
|
|
Ia:RP2D
Time Frame: 2 years
|
Recommended Phase II Dose(RP2D)
|
2 years
|
|
Ib:objective response rate(ORR);
Time Frame: 2 years
|
Efficacy evaluated by the investigator according to RECIST v1.1: objective response rate (ORR);
|
2 years
|
|
Ib:AE
Time Frame: 2 years
|
Type, frequency, duration, severity and characteristics of Adverse Events (AEs) according to NCI-CTCAE
|
2 years
|
|
Ib:SAE
Time Frame: 2 years
|
Type, frequency, duration, severity and characteristics of serious adverse events(SAEs) according to NCI-CTCAE
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ia:the concentration of RP903 or its metabolites (if applicable)
Time Frame: 1 years
|
the concentration of RP903 or its metabolites (if applicable) in individual subjects at different time points after administration;
|
1 years
|
|
Ia:Cmax
Time Frame: 1 years
|
peak concentration
|
1 years
|
|
Ia:Ctrough
Time Frame: 1 years
|
trough concentration
|
1 years
|
|
Ia:Tmax
Time Frame: 1 years
|
time to peak
|
1 years
|
|
Ia:AUC0-t and AUC0-∞
Time Frame: 1 years
|
area under the plasma drug concentration-time curve
|
1 years
|
|
Ia:Vd/F
Time Frame: 1 years
|
distribution volume
|
1 years
|
|
Ia:CL/F
Time Frame: 1 years
|
clearance
|
1 years
|
|
Ia:t1/2
Time Frame: 1 years
|
half-life
|
1 years
|
|
Ia:Rac
Time Frame: 1 years
|
cumulative factor
|
1 years
|
|
Ia:ORR
Time Frame: 1 years
|
objective response rate
|
1 years
|
|
Ia:DoR
Time Frame: 1 years
|
duration of response
|
1 years
|
|
Ia:DCR
Time Frame: 1 years
|
disease control rate
|
1 years
|
|
Ia:TTR
Time Frame: 1 years
|
time to response
|
1 years
|
|
Ia:PFS
Time Frame: 1 years
|
progression-free survival
|
1 years
|
|
Ia:OS
Time Frame: 1 years
|
overall survival
|
1 years
|
|
Ib:safety:AE
Time Frame: 2 years
|
Type, frequency, duration, severity and characteristics of serious adverse events(SAEs) according to NCI-CTCAE
|
2 years
|
|
Ib:safety:SAE
Time Frame: 2 years
|
Type, frequency, duration, severity and characteristics of serious adverse events(SAEs) according to NCI-CTCAE
|
2 years
|
|
Ib:safety:Body temperature
Time Frame: 2 years
|
Body temperature changes according to NCI-CTCAE
|
2 years
|
|
Ib:safety:pulse
Time Frame: 2 years
|
pulse changes according to NCI-CTCAE
|
2 years
|
|
Ib:safety:respiratory rate
Time Frame: 2 years
|
respiratory rate changes according to NCI-CTCAE
|
2 years
|
|
Ib:safety: blood pressure
Time Frame: 2 years
|
blood pressure changes according to NCI-CTCAE
|
2 years
|
|
Ib:safety:laboratory test
Time Frame: 2 years
|
laboratory test changes according to NCI-CTCAE
|
2 years
|
|
Ib:safety:heart rate
Time Frame: 2 years
|
heart rate changes according to NCI-CTCAE
|
2 years
|
|
Ib:safety:QT
Time Frame: 2 years
|
QT changes according to NCI-CTCAE
|
2 years
|
|
Ib:safety:QTcF
Time Frame: 2 years
|
QTcF changes according to NCI-CTCAE
|
2 years
|
|
Ib:safety:PR
Time Frame: 2 years
|
PR changes according to NCI-CTCAE
|
2 years
|
|
Ib:DoR
Time Frame: 1 years
|
duration of response
|
1 years
|
|
Ib:DCR
Time Frame: 1 years
|
disease control rate
|
1 years
|
|
Ib:TTR
Time Frame: 1 years
|
time to response
|
1 years
|
|
Ib:PFS
Time Frame: 1 years
|
progression-free survival
|
1 years
|
|
Ib:OS
Time Frame: 2 years
|
overall survival
|
2 years
|
|
Ib:Concentrations of RP903 or its metabolites
Time Frame: 1 years
|
Concentrations of RP903 or its metabolites (if applicable) in individual subjects at different time points after dosing.
|
1 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
blood glucose
Time Frame: 28days
|
To explore the relationship between blood glucose levels in peripheral blood and efficacy;
|
28days
|
|
Insulin
Time Frame: 28days
|
To explore the relationship between Insulin levels in peripheral blood and efficacy;
|
28days
|
|
C-peptide
Time Frame: 28days
|
To explore the relationship between C-peptide levels in peripheral blood and efficacy;
|
28days
|
|
PIK3CA mutation status
Time Frame: 28days
|
To explore the correlation between peripheral blood and tumor tissue PIK3CA mutation status in different indications;
|
28days
|
|
peripheral blood PIK3CA mutation
Time Frame: 28days
|
To explore the correlation between peripheral blood PIK3CA mutation and efficacy;
|
28days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Endocrine System Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Uterine Diseases
- Genital Diseases, Female
- Endocrine Gland Neoplasms
- Ovarian Diseases
- Adnexal Diseases
- Genital Neoplasms, Female
- Gonadal Disorders
- Skin Diseases
- Breast Diseases
- Uterine Cervical Diseases
- Uterine Neoplasms
- Skin and Connective Tissue Diseases
- Ovarian Neoplasms
- Breast Neoplasms
- Uterine Cervical Neoplasms
- Endometrial Neoplasms
Other Study ID Numbers
- JS105-001-I
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.